Synergy Pharmaceuticals Inc. (SGYP)

0.01
0.00 4.48
OTC : Health Technology
Prev Close 0.01
Open 0.01
Day Low/High 0.01 / 0.01
52 Wk Low/High 0.01 / 0.04
Volume 697.61K
Avg Volume 19.48M
Exchange OTC
Shares Outstanding 248.04M
Market Cap 7.44M
EPS -1.00
Div & Yield N.A. (N.A)

Latest News

Synergy Pharmaceuticals Announces Completion Of Sale To Bausch Health

Synergy Pharmaceuticals Announces Completion Of Sale To Bausch Health

NEW YORK, March 6, 2019 /PRNewswire/ -- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (the "Company" or "Synergy"), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today confirmed that...

Bausch Health Completes Acquisition Of Certain Assets Of Synergy Pharmaceuticals Inc.

Bausch Health Completes Acquisition Of Certain Assets Of Synergy Pharmaceuticals Inc.

LAVAL, Quebec, March 6, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that the Company has completed the acquisition of certain assets of Synergy Pharmaceuticals Inc.

Rules of Biotech Investing Change, and So Must Biotech Investors

Rules of Biotech Investing Change, and So Must Biotech Investors

One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.

Synergy Pharmaceuticals Receives Court Approval For The Sale Of Its Assets To Bausch Health

Synergy Pharmaceuticals Receives Court Approval For The Sale Of Its Assets To Bausch Health

NEW YORK, March 1, 2019 /PRNewswire/ -- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (the "Company" or "Synergy"), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today confirmed that...

Bausch Health To Acquire Certain Assets Of Synergy Pharmaceuticals Inc.

Bausch Health To Acquire Certain Assets Of Synergy Pharmaceuticals Inc.

Bausch Health and Synergy to Seek Bankruptcy Court Approval of Sale on March 1, 2019 LAVAL, Quebec, Feb.

Synergy Pharmaceuticals Confirms Bausch Health As Successful Bidder For Its Business Assets

Synergy Pharmaceuticals Confirms Bausch Health As Successful Bidder For Its Business Assets

NEW YORK, Feb. 26, 2019 /PRNewswire/ -- Synergy Pharmaceuticals Inc.

Investor Alert: Kaplan Fox Announces Investigation Of Synergy Pharmaceuticals Inc.

Investor Alert: Kaplan Fox Announces Investigation Of Synergy Pharmaceuticals Inc.

NEW YORK, Feb. 20, 2019 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Synergy Pharmaceuticals Inc. - SGYP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Synergy Pharmaceuticals Inc. - SGYP

NEW YORK, Feb. 13, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Synergy Pharmaceuticals Inc.

Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.

Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.

Strategic Acquisition Will Enhance the Salix Gastroenterology Portfolio LAVAL, Quebec, Dec.

Synergy Pharmaceuticals Announces Agreement For Bausch Health To Acquire Its Business Assets

Synergy Pharmaceuticals Announces Agreement For Bausch Health To Acquire Its Business Assets

Company Initiates Voluntary Chapter 11 Process to Effectuate Sale; Secures Commitment for DIP Financing to Support Normal-Course Operations

Synergy Pharmaceuticals Reports Third Quarter 2018 Financial Results And Business Update

Synergy Pharmaceuticals Reports Third Quarter 2018 Financial Results And Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended...

Synergy Pharmaceuticals Names Dr. Melvin K. Spigelman Chairman

Synergy Pharmaceuticals Names Dr. Melvin K. Spigelman Chairman

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that Melvin K.

Synergy Pharmaceuticals Provides Business Update

Synergy Pharmaceuticals Provides Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) (the "Company" or "Synergy"), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today provided a business update.

Synergy Pharmaceuticals Presents New Analyses Supporting The Use Of TRULANCE® (plecanatide) In Two Patient Populations At The American College Of Gastroenterology (ACG) Annual Scientific Meeting

Synergy Pharmaceuticals Presents New Analyses Supporting The Use Of TRULANCE® (plecanatide) In Two Patient Populations At The American College Of Gastroenterology (ACG) Annual Scientific Meeting

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that the company will present new analyses that further reinforce the...

Synergy Pharmaceuticals To Present New Analyses Of TRULANCE® (Plecanatide) At The American College Of Gastroenterology (ACG) Annual Scientific Meeting

Synergy Pharmaceuticals To Present New Analyses Of TRULANCE® (Plecanatide) At The American College Of Gastroenterology (ACG) Annual Scientific Meeting

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that two posters will be presented at the American College of...

Synergy Pharmaceuticals Strengthens Coverage For TRULANCE® (plecanatide) With Key New Market Access Wins

Synergy Pharmaceuticals Strengthens Coverage For TRULANCE® (plecanatide) With Key New Market Access Wins

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced several new formulary wins improving TRULANCE 2018 and 2019 coverage status...

First Week Of January 2021 Options Trading For Synergy Pharmaceuticals (SGYP)

First Week Of January 2021 Options Trading For Synergy Pharmaceuticals (SGYP)

Investors in Synergy Pharmaceuticals Inc saw new options begin trading this week, for the January 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week Of SGYP April 2019 Options Trading

First Week Of SGYP April 2019 Options Trading

Investors in Synergy Pharmaceuticals Inc saw new options begin trading this week, for the April 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Synergy Pharmaceuticals Reports Second Quarter 2018 Financial Results And Business Update

Synergy Pharmaceuticals Reports Second Quarter 2018 Financial Results And Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended June 30,...

Synergy Pharmaceuticals Announces TRULANCE® (plecanatide) Added To Express Scripts 2019 National Preferred Formulary List

Synergy Pharmaceuticals Announces TRULANCE® (plecanatide) Added To Express Scripts 2019 National Preferred Formulary List

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that leading U.

Synergy Pharmaceuticals Announces License Agreement With Luoxin Pharmaceutical Group For TRULANCE® (plecanatide) In China

Synergy Pharmaceuticals Announces License Agreement With Luoxin Pharmaceutical Group For TRULANCE® (plecanatide) In China

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) announced today that the company has entered into a license agreement with Luoxin Pharmaceutical Group Co.

Synergy Pharmaceuticals Announces Amendment To CRG Debt Agreement

Synergy Pharmaceuticals Announces Amendment To CRG Debt Agreement

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has received a waiver to extend the draw down date of the second...

Synergy Pharmaceuticals To Present New Analysis Of Therapeutic Risk And Benefit Of TRULANCE® (plecanatide) And Linaclotide In Chronic Idiopathic Constipation (CIC) Patients At Digestive Disease Week (DDW)

Synergy Pharmaceuticals To Present New Analysis Of Therapeutic Risk And Benefit Of TRULANCE® (plecanatide) And Linaclotide In Chronic Idiopathic Constipation (CIC) Patients At Digestive Disease Week (DDW)

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that the company will present a new risk/benefit analysis from pooled Phase...

Synergy Pharmaceuticals Highlights New Data At Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency To Chronic Idiopathic Constipation (CIC) And Irritable Bowel Syndrome With Constipation (IBS-C)

Synergy Pharmaceuticals Highlights New Data At Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency To Chronic Idiopathic Constipation (CIC) And Irritable Bowel Syndrome With Constipation (IBS-C)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, announced today new data presented at Digestive Disease Week (DDW) 2018 showing chronic...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAP, BKHU, EDN, ESSA, FRAN, FSV, IESC, KMX, QTNA, SMCI, STRL Downgrades: BECN, BOSC, CHEF, CSS, MIDD, NL, RST, SCOR, VMW Initiations: SGYP Read on to get TheStreet Quant Ratings' detailed report:

Synergy Pharmaceuticals To Present New Data At Digestive Disease Week (DDW)

Synergy Pharmaceuticals To Present New Data At Digestive Disease Week (DDW)

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced three abstracts that will be presented at Digestive Disease Week (DDW) in...

Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results And Business Update

Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results And Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended March...

Synergy Pharmaceuticals To Report First Quarter 2018 Financial Results And Host Conference Call And Webcast

Synergy Pharmaceuticals To Report First Quarter 2018 Financial Results And Host Conference Call And Webcast

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced it intends to release its first quarter 2018 financial results after the...

TheStreet Quant Rating: E+ (Sell)